angioplasty

Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000&nbsp;patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC&nbsp;2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-twilight-complex-ticagrelor-monotherapy-in-the-most-dangerous-angioplasties/" title="Read more" >...</a>

ACC 2020 Virtual | El controvertido estudio ISCHEMIA llega finalmente a NEJM

Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM

In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial that called the attention of all cardiologists. We had to wait until March to read the fine print; back then, a global pandemic such as the current one seemed out of a science-fiction tale. The world has changed<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-controversial-trial-ischemia-finally-in-nejm/" title="Read more" >...</a>

ACC 2020 Virtual | TAILOR PCI: indicar clopidogrel en base a los genes no cambia la historia

Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to meet its primary endpoint. Using genotype to individualize treatment with a P2Y12 inhibitor in patients with acute coronary syndrome or stable patients after a scheduled angioplasty compared with conventional treatment with clopidogrel does not reduce the risk of<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-tailor-pci-gene-based-prescribing-of-clopidogrel-does-not-change-outcomes/" title="Read more" >...</a>

La ATC es una alternativa válida en el TCI

5 Years of FAST-MI: If Unable to Meet the Timeline, Thrombolization Is the Way to Go

A large proportion of patients undergo primary angioplasty beyond the timelines recommended by clinical practice guidelines. These patients have poorer 5-year outcomes compared with those subjected to a pharmaco-invasive strategy. ST-segment elevation myocardial infarction guidelines recommend primary angioplasty as the strategy of choice within 120&nbsp;min after a diagnostic electrocardiography. If that is not possible, thrombolytic<a href="https://solaci.org/en/2020/03/18/5-years-of-fast-mi-if-unable-to-meet-the-timeline-thrombolization-is-the-way-to-go/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Coated Balloons in Infrapopliteal Disease: Much Ado About Nothing

The revascularization of tibial arteries in patients with critical lower limb ischemia using drug-coated balloons vs. conventional angioplasty resulted in comparable long-term outcomes in terms of both safety and efficacy. Paclitaxel exposure was not related to a higher risk of amputation or all-cause mortality at 5&nbsp;years (which is the good news for much questioned drug-coated<a href="https://solaci.org/en/2020/03/16/drug-coated-balloons-in-infrapopliteal-disease-much-ado-about-nothing/" title="Read more" >...</a>

mas-leido-febrero-eng-420x283-compressor

The Most Read Scientific Articles of February

01- Alternatives for Patients Allergic to Aspirin The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a recommendation to use monotherapy with the most potent antiaggregant we<a href="https://solaci.org/en/2020/03/11/the-most-read-scientific-articles-of-february/" title="Read more" >...</a>

isquemia crítica de miembros inferiores

New European Guidelines on the Management of Lower Limb Acute Ischemia

Clinical practice guidelines are usually tedious and, frankly, while a lot of people make an enormous effort to write them, they are ultimately read in full by just a few. These new European Guidelines on the Management of Lower Limb Acute Ischemia represent a special team effort, since they include physicians, cardiologists, surgeons, and interventionists,<a href="https://solaci.org/en/2020/02/07/new-european-guidelines-on-the-management-of-lower-limb-acute-ischemia/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

Repeat Revascularization Is Not Benign, at Least in Left Main Disease

After the “EXCEL scandal” at the end of last year, study investigators have been publishing explanations and sub-studies that were planned from the beginning, but which can still be interpreted as explanations. This sub-study states that revascularization was more common in the angioplasty arm, but only revascularizations performed on the target lesion, regardless of the<a href="https://solaci.org/en/2020/02/07/repeat-revascularization-is-not-benign-at-least-in-left-main-disease/" title="Read more" >...</a>

La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

Ticagrelor Monotherapy One Month After DES Implantation

The GLOBAL LEADERS study includes a pre-specified sub-study, GLASSY, that showed that ticagrelor monotherapy after one month of dual antiplatelet therapy is non-inferior (but not superior) to conventional treatment in terms of ischemic events. As regards safety, ticagrelor monotherapy did not decrease major bleeding compared with conventional therapy. The GLOBAL LEADERS randomized 15,991&nbsp;patients who required<a href="https://solaci.org/en/2020/01/13/ticagrelor-monotherapy-one-month-after-des-implantation/" title="Read more" >...</a>

Impella

Impella: A Revolutionary Device Being Questioned

Observational studies (with their subsequent limitations) show a possible increase in adverse events and costs with the use of the Impella device. Two large observational studies stirred doubts regarding the good performance of new circulatory support devices in real-world daily clinical practice. There were more adverse events, including in-hospital death and major bleeding, and more<a href="https://solaci.org/en/2020/01/13/impella-a-revolutionary-device-being-questioned/" title="Read more" >...</a>

Top